CLNNW Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Mai 2024 @ 22:00):

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics...

Stats
Tagesvolumen	1 200.00
Durchschnittsvolumen	0.00
Marktkapitalisierung	42.25M
EPS	$-0.000290 ( 2023-06-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-28	Desai Arjun Jj	Buy	33 040	Stock Options (Right to buy)
2023-11-28	Jacobovitz Shalom	Buy	42 736	Stock Options (Right to buy)
2023-11-28	Matlin David J	Buy	56 024	Stock Options (Right to buy)
2023-11-28	Kiernan Matthew	Buy	28 730	Stock Options (Right to buy)
2023-11-28	Mosca Alison	Buy	43 814	Stock Options (Right to buy)

INSIDER POWER
99.47
Last 99 transactions
Buy: 47 544 964 \| Sell: 666 194

Clene Inc. Korrelation

10 Am meisten positiv korreliert
HDL	0.922
RAY	0.918

10 Am meisten negativ korreliert
BOTT	-0.804

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Clene Inc. Finanzdaten

Annual	2023
Umsatz:	$654 000
Bruttogewinn:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2023
Umsatz:	$654 000
Bruttogewinn:	$-1.17M (-179.20 %)
EPS:	$-0.470

FY	2022
Umsatz:	$473 000
Bruttogewinn:	$447 000 (94.50 %)
EPS:	$-0.230

FY	2021
Umsatz:	$723 000
Bruttogewinn:	$434 000 (60.03 %)
EPS:	$0

Financial Reports:

No articles found.

Clene Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clene Inc.

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain\'s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson\'s Diseases. The company\'s products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.